2024 annual financial data
Silexion Therapeutics 2024 Operating cash flow growth
Direct answer
Operating cash flow growth was -85.38%.
Operating income was -12,571,000 USD and net income was -16,443,000 USD.
Operating cash flow was -8,396,000 USD.
Get free Silexion Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -12,571,000 USD
- Net income
- -16,443,000 USD
- Operating cash flow
- -8,396,000 USD